Schrödinger, founded in 1990, develops software and computational platforms that combine physics-based molecular simulation with machine learning to accelerate drug and materials discovery. The company's approach integrates rigorous physics with modern artificial intelligence to predict molecular behaviour and guide research decisions, helping pharmaceutical companies, biotech firms, and materials researchers identify promising compounds more efficiently than traditional trial-and-error methods.
The platform has been adopted by over 1,600 organizations across 70 countries. Schrödinger operates not merely as a software vendor but actively applies its tools through collaborative research partnerships, where its computational predictions have translated into experimental results and identified compounds that researchers might otherwise have overlooked.
The company's team comprises scientists, engineers, and computational chemists with expertise spanning physics, chemistry, biology, and computer science. This multidisciplinary structure reflects Schrödinger's core mission: combining domain-specific scientific knowledge with computational innovation to transform molecular discovery.
